Abstract
Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.
Keywords: Nicotine replacement therapy, bupropion, varenicline, psychiatric, clonidine, nortriptyline, lozenge, cessation, acetylcholine, pulsatile, alkaloids, galenic, libitum, dyspepsia, tremor, insomnia
Current Pharmaceutical Design
Title: Pharmacotherapy for Smoking Cessation: Present and Future
Volume: 17 Issue: 14
Author(s): Henri-Jean Aubin, Laurent Karila and Michel Reynaud
Affiliation:
Keywords: Nicotine replacement therapy, bupropion, varenicline, psychiatric, clonidine, nortriptyline, lozenge, cessation, acetylcholine, pulsatile, alkaloids, galenic, libitum, dyspepsia, tremor, insomnia
Abstract: Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.
Export Options
About this article
Cite this article as:
Aubin Henri-Jean, Karila Laurent and Reynaud Michel, Pharmacotherapy for Smoking Cessation: Present and Future, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150837
DOI https://dx.doi.org/10.2174/138161211796150837 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry The Small Bowel: An Imaging Guide
Current Medical Imaging Classic Histamine H1 Receptor Antagonists: A Critical Review of their Metabolic and Pharmacokinetic Fate from a Birds Eye View
Current Drug Metabolism Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Adenovirus Vectors and Subviral Particles for Protein and Peptide Delivery
Current Gene Therapy Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology Ascaris lumbricoides: An Overview of Therapeutic Targets
Infectious Disorders - Drug Targets Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Chronic Spontaneous Urticaria: Epidemiological Characteristics Focusing on the Histocompatibility Profile and Presence of Antibodies
Inflammation & Allergy - Drug Targets (Discontinued) Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews The Role of Antihistamine Drugs in Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery Phenolics Constituents of Different Types of Propolis and their Antimicrobial Activities
Anti-Infective Agents Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design